Roche Holding AG $RHHBY is Saratoga Research & Investment Management’s 8th Largest Position

Saratoga Research & Investment Management decreased its holdings in Roche Holding AG (OTCMKTS:RHHBY) by 4.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,832,770 shares of the company’s stock after selling 87,315 shares during the quarter. Roche accounts for about 5.0% of Saratoga Research & Investment Management’s holdings, making the stock its 8th biggest holding. Saratoga Research & Investment Management’s holdings in Roche were worth $94,516,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Boston Common Asset Management LLC boosted its stake in shares of Roche by 1.9% in the third quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company’s stock valued at $15,049,000 after purchasing an additional 6,720 shares during the period. Altrius Capital Management Inc boosted its stake in shares of Roche by 4.0% in the third quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock valued at $8,290,000 after purchasing an additional 7,659 shares during the period. Meritage Portfolio Management purchased a new position in shares of Roche in the fourth quarter valued at approximately $4,372,000. Diversified Trust Co. boosted its stake in shares of Roche by 1.8% in the fourth quarter. Diversified Trust Co. now owns 58,927 shares of the company’s stock valued at $3,051,000 after purchasing an additional 1,046 shares during the period. Finally, S&CO Inc. boosted its stake in shares of Roche by 2.5% in the fourth quarter. S&CO Inc. now owns 53,444 shares of the company’s stock valued at $2,767,000 after purchasing an additional 1,290 shares during the period.

Roche Stock Performance

Shares of Roche stock opened at $51.09 on Friday. Roche Holding AG has a 52-week low of $37.51 and a 52-week high of $60.85. The company has a 50 day moving average of $50.70 and a 200 day moving average of $51.33. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Argus raised shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Citigroup assumed coverage on shares of Roche in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. TD Cowen reiterated a “hold” rating on shares of Roche in a research note on Tuesday, February 10th. Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price target for the company in a research note on Friday, April 24th. Finally, Wolfe Research reiterated an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $51.50.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.